600062 华润双鹤
已收盘 11-06 15:00:00
资讯
新帖
简况
股市必读：华润双鹤(600062)股东户数5.77万户，较上期增加0.51%
证券之星 · 10-26
股市必读：华润双鹤(600062)股东户数5.77万户，较上期增加0.51%
每周股票复盘：华润双鹤（600062）三季度净利增6.71%
证券之星 · 10-25
每周股票复盘：华润双鹤（600062）三季度净利增6.71%
华润双鹤（600062）披露公司2021年限制性股票激励计划预留授予部分第二个解除限售期解除限售条件成就的公告，10月24日股价下跌0.37%
证券之星 · 10-24
华润双鹤（600062）披露公司2021年限制性股票激励计划预留授予部分第二个解除限售期解除限售条件成就的公告，10月24日股价下跌0.37%
华润双鹤 - 2025年前三季度净利润为人民币13.9亿元
美股速递 · 10-24
华润双鹤 - 2025年前三季度净利润为人民币13.9亿元
股价高位回撤35%，“中药茅”Q3净利继续“崩盘”
《投资有道》杂志 · 10-22
股价高位回撤35%，“中药茅”Q3净利继续“崩盘”
华润双鹤(600062.SH)子公司阿法骨化醇软胶囊获得药品注册证书
智通财经 · 10-20
华润双鹤(600062.SH)子公司阿法骨化醇软胶囊获得药品注册证书
华润双鹤(600062.SH)子公司波生坦分散片获得药品注册证书
智通财经 · 09-29
华润双鹤(600062.SH)子公司波生坦分散片获得药品注册证书
华润双鹤(600062.SH)：盐酸替罗非班氯化钠注射液获得药品注册证书
智通财经 · 09-16
华润双鹤(600062.SH)：盐酸替罗非班氯化钠注射液获得药品注册证书
每周股票复盘：华润双鹤（600062）拟发行公司债券并实施中期分红
证券之星 · 09-13
每周股票复盘：华润双鹤（600062）拟发行公司债券并实施中期分红
华润双鹤(600062.SH)子公司腹膜透析液(乳酸盐)系列药品获得药品补充申请批准通知书
智通财经 · 09-11
华润双鹤(600062.SH)子公司腹膜透析液(乳酸盐)系列药品获得药品补充申请批准通知书
每周股票复盘：华润双鹤（600062）拟每10股派1元并发行不超30亿公司债
证券之星 · 09-06
每周股票复盘：华润双鹤（600062）拟每10股派1元并发行不超30亿公司债
华润双鹤(600062.SH)控股子公司浙江新赛科通过GMP符合性检查
智通财经 · 09-02
华润双鹤(600062.SH)控股子公司浙江新赛科通过GMP符合性检查
华润双鹤：氯化钾注射液获批
格隆汇 · 08-31
华润双鹤：氯化钾注射液获批
华润双鹤(600062.SH)：氯化钾注射液获得药品补充申请批准通知书
智通财经 · 08-31
华润双鹤(600062.SH)：氯化钾注射液获得药品补充申请批准通知书
华润双鹤：公司药品获批准通知书及药品注册证书
金融界 · 08-27
华润双鹤：公司药品获批准通知书及药品注册证书
股市必读：华润双鹤中报 - 第二季度单季净利润同比下降12.11%
证券之星 · 08-25
股市必读：华润双鹤中报 - 第二季度单季净利润同比下降12.11%
每周股票复盘：华润双鹤（600062）股东户数减少，半年度营收下降
证券之星 · 08-23
每周股票复盘：华润双鹤（600062）股东户数减少，半年度营收下降
华润双鹤与河南投资集团签署战略合作框架协议
格隆汇 · 08-23
华润双鹤与河南投资集团签署战略合作框架协议
华润医药-华润双鹤拟每10股派发现金股息人民币1元（含税）
美股速递 · 08-22
华润医药-华润双鹤拟每10股派发现金股息人民币1元（含税）
华润双鹤：2025年上半年净利润同比减少6.79%
金融界 · 08-22
华润双鹤：2025年上半年净利润同比减少6.79%
加载更多
公司概况
公司名称：
华润双鹤药业股份有限公司
所属行业：
医药制造业
上市日期：
1997-05-22
主营业务：
华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务和输液业务三大业务。公司的主要产品是输液业务平台、慢病业务平台、专科业务平台、原料药、复方利血平氨苯蝶啶片(0号)、左炔诺孕酮片(金毓婷)、胞磷胆碱钠片(诺百益)、缬沙坦氢氯噻嗪片(复穗悦)、软袋(含直立式)。
发行价格：
6.69
{"stockData":{"symbol":"600062","market":"SH","secType":"STK","nameCN":"华润双鹤","latestPrice":19.28,"timestamp":1762412401000,"preClose":19.24,"halted":0,"volume":5297509,"delay":0,"changeRate":0.0021,"floatShares":1033000000,"shares":1039000000,"eps":1.5213,"marketStatus":"已收盘","change":0.04,"latestTime":"11-06 15:00:00","open":19.23,"high":19.3,"low":19.17,"amount":102000000,"amplitude":0.0068,"askPrice":19.29,"askSize":1047,"bidPrice":19.28,"bidSize":341,"shortable":0,"etf":0,"ttmEps":1.5213,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1762479000000},"marketStatusCode":5,"adr":0,"adjPreClose":19.24,"symbolType":"stock","openAndCloseTimeList":[[1762392600000,1762399800000],[1762405200000,1762412400000]],"highLimit":21.16,"lowLimit":17.32,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1038757509,"isCdr":false,"pbRate":1.77,"roa":"--","peRate":12.673371,"roe":"12.34%","epsLYR":1.5838,"committee":-0.132303,"marketValue":20027000000,"turnoverRate":0.0051,"status":0,"floatMarketCap":19909000000},"requestUrl":"/m/hq/s/600062","defaultTab":"news","newsList":[{"id":"2578665448","title":"股市必读：华润双鹤(600062)股东户数5.77万户，较上期增加0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578665448","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578665448?lang=zh_cn&edition=full","pubTime":"2025-10-27 03:32","pubTimestamp":1761507133,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，华润双鹤报收于18.97元，下跌0.37%，换手率0.58%，成交量5.98万手，成交额1.13亿元。股本股东变化股东户数变动近日华润双鹤披露，截至2025年9月30日公司股东户数为5.77万户，较6月30日增加295.0户，增幅为0.51%。归属于上市公司股东的所有者权益：本报告期末：11,318,550,040.76元，较年度末增加8.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700000890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600062","BK0185","BK0175","BK0028","BK0188","BK0010"],"gpt_icon":0},{"id":"2578028295","title":"每周股票复盘：华润双鹤（600062）三季度净利增6.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578028295","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578028295?lang=zh_cn&edition=full","pubTime":"2025-10-26 02:56","pubTimestamp":1761418570,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，华润双鹤报收于18.97元，较上周的18.87元上涨0.53%。本周，华润双鹤10月22日盘中最高价报19.12元。本周关注点来自业绩披露要点：华润双鹤第三季度归母净利润同比增长6.71%。股本股东变化截至2025年9月30日，华润双鹤股东户数为5.77万户，较6月30日增加295户，增幅0.51%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0185","BK0188","BK0239","BK0175","BK0028","BK0010"],"gpt_icon":0},{"id":"2577517483","title":"华润双鹤（600062）披露公司2021年限制性股票激励计划预留授予部分第二个解除限售期解除限售条件成就的公告，10月24日股价下跌0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577517483","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577517483?lang=zh_cn&edition=full","pubTime":"2025-10-24 22:16","pubTimestamp":1761315410,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，华润双鹤报收于18.97元，较前一交易日下跌0.37%，最新总市值为197.05亿元。近日，华润双鹤药业股份有限公司发布关于公司2021年限制性股票激励计划预留授予部分第二个解除限售期解除限售条件成就的公告。公告显示，本次解除限售股票数量为347,068股，涉及激励对象40人，约占公司总股本的0.03%。薪酬与考核委员会、监事会及法律顾问均发表同意意见。公司将在办理相关手续后发布股份上市公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400042691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0010","BK0188","BK0028","600062","BK0239","BK0175"],"gpt_icon":0},{"id":"1192191648","title":"华润双鹤 - 2025年前三季度净利润为人民币13.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192191648","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192191648?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:15","pubTimestamp":1761297340,"startTime":"0","endTime":"0","summary":"华润双鹤 - 2025年前三季度净利润为人民币13.9亿元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0239","BK1570","BK0175","BK0185","03320","BK0010","BK0028","BK0188","600062"],"gpt_icon":0},{"id":"2577535031","title":"股价高位回撤35%，“中药茅”Q3净利继续“崩盘”","url":"https://stock-news.laohu8.com/highlight/detail?id=2577535031","media":"《投资有道》杂志","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577535031?lang=zh_cn&edition=full","pubTime":"2025-10-22 17:37","pubTimestamp":1761125820,"startTime":"0","endTime":"0","summary":"“中药茅”片仔癀三季报正式出炉，净利润连续两个季度大幅下滑。片仔癀则处于“双下滑”队列，营收同比下滑4.81%，归母净利润同比下滑16.22%。2025年上半年，片仔癀的销售毛利率为40.41%，在行业中排名第52位。股价回撤35%，近一年大宗交易成交超2.8亿元三季报发出后，片仔癀股价连续三天下跌。片仔癀的市值一度接近3000亿元，被市场称为“中药茅”。而在2025年上半年，片仔癀归母净利润较上年同期减少约2.8亿元，扣非归母净利润减少约2.98亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-22/doc-infuuiip0388695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0264606111.USD","BK0239","BK0250","LU0572940350.SGD","BK0015","600739","BK0185","600436","BK0183","LU1580142542.USD","LU1328615791.USD","BK0175","BK0010","LU0821914370.USD","LU1048596156.SGD","LU0572939691.SGD","601166","600062","BK0028","BK0144","300436","BK0188","LU1781817850.SGD","601377","BK0074","BK0187","BK0278","BK0276","BK0196","BK0012"],"gpt_icon":0},{"id":"2576832424","title":"华润双鹤(600062.SH)子公司阿法骨化醇软胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2576832424","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576832424?lang=zh_cn&edition=full","pubTime":"2025-10-20 17:31","pubTimestamp":1760952706,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司北京万辉双鹤药业有限责任公司(简称“万辉双鹤”)收到了国家药品监督管理局颁发的阿法骨化醇软胶囊《药品注册证书》。阿法骨化醇软胶囊适用于治疗内源性1,25-二羟基维生素D3产生不足所致的钙代谢紊乱性疾病。例如肾性骨营养不良、术后性或特发性甲状旁腺功能低下症、假性甲状旁腺功能低下症、作为第三性甲状旁腺功能亢进的辅助治疗、抗维生素D性佝偻病或骨软化症、维生素D依赖型佝偻病、新生儿低钙血症或佝偻病、钙吸收不良症、骨质疏松症、吸收不良性及营养性佝偻病及骨软化症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)子公司阿法骨化醇软胶囊获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600062","BK0028","BK0188","BK0239","BK0010","BK0175","BK0185"],"gpt_icon":0},{"id":"2571894883","title":"华润双鹤(600062.SH)子公司波生坦分散片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2571894883","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571894883?lang=zh_cn&edition=full","pubTime":"2025-09-29 17:56","pubTimestamp":1759139782,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司华润双鹤利民药业(济南)有限公司(简称“双鹤利民”)收到了国家药品监督管理局(简称“国家药监局”)颁发的波生坦分散片《药品注册证书》。波生坦分散片的适应症为肺动脉高压(PAH)(WHO第1组)：用于在年龄≥3岁的儿科特发性或先天性PAH患者中改善肺血管阻力(PVR);用于WHO功能分级II级-IV级的肺动脉高压(PAH)(WHO第1组)的成人患者的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)子公司波生坦分散片获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","600062","BK0175","BK0188","BK0185","BK0010","BK0239"],"gpt_icon":0},{"id":"2567108204","title":"华润双鹤(600062.SH)：盐酸替罗非班氯化钠注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2567108204","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567108204?lang=zh_cn&edition=full","pubTime":"2025-09-16 17:00","pubTimestamp":1758013243,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司安徽双鹤药业有限责任公司(以下简称“安徽双鹤”)收到了国家药品监督管理局(以下简称“国家药监局”)颁发的盐酸替罗非班氯化钠注射液(以下简称“该药品”)《药品注册证书》。据悉，盐酸替罗非班氯化钠注射液是一种抗血小板凝集药，主要用于末次胸痛发作12小时之内且伴有ECG改变和/或心肌酶升高的非ST段抬高型急性冠脉综合征(NSTE-ACS)成年患者，预防早期心肌梗死。用于计划进行直接PCI的急性心肌梗死患者(STEMI)，以减少重大心血管事件的发生。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1345811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"华润双鹤(600062.SH)：盐酸替罗非班氯化钠注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0185","BK0188","BK0010","BK0239","BK0175","600062"],"gpt_icon":0},{"id":"2567526133","title":"每周股票复盘：华润双鹤（600062）拟发行公司债券并实施中期分红","url":"https://stock-news.laohu8.com/highlight/detail?id=2567526133","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567526133?lang=zh_cn&edition=full","pubTime":"2025-09-14 02:19","pubTimestamp":1757787551,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，华润双鹤报收于19.18元，较上周的19.38元下跌1.03%。本周，华润双鹤9月9日盘中最高价报19.6元。本周关注点公司公告汇总：华润双鹤股东大会审议通过2025年半年度利润分配及公开发行公司债券相关议案。华润双鹤2025年第二次临时股东会决议公告显示，会议于2025年9月9日召开，由董事赵骞主持，采用现场与网络投票相结合方式，表决程序符合《公司法》及公司章程规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400000426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0175","BK0239","BK0185","BK0010","BK0028","600062"],"gpt_icon":0},{"id":"2566968294","title":"华润双鹤(600062.SH)子公司腹膜透析液(乳酸盐)系列药品获得药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2566968294","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566968294?lang=zh_cn&edition=full","pubTime":"2025-09-11 16:53","pubTimestamp":1757580789,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司上海长征富民金山制药有限公司(简称“上海长富”)收到了国家药品监督管理局(简称“国家药监局”)颁发的腹膜透析液(乳酸盐-G1.5%)、腹膜透析液(乳酸盐-G2.5%)(简称“该系列药品”)《药品补充申请批准通知书》。腹膜透析液(乳酸盐)主要适用于因非透析治疗无效而需要连续不卧床性腹膜透析治疗的急性及慢性肾功能衰竭患者。本次《药品补充申请批准通知书》的获得是对腹膜透析液(乳酸盐)规格的进一步补充，将有利于发挥该系列药品未来市场销售和市场竞争的潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1344120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)子公司腹膜透析液(乳酸盐)系列药品获得药品补充申请批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","600062","BK0175","BK0185","BK0010","BK0188"],"gpt_icon":0},{"id":"2565351064","title":"每周股票复盘：华润双鹤（600062）拟每10股派1元并发行不超30亿公司债","url":"https://stock-news.laohu8.com/highlight/detail?id=2565351064","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565351064?lang=zh_cn&edition=full","pubTime":"2025-09-07 02:20","pubTimestamp":1757182826,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘，华润双鹤报收于19.38元，较上周的19.45元下跌0.36%。公司公告汇总华润双鹤药业股份有限公司拟召开2025年第二次临时股东会，审议2025年半年度利润分配、公开发行公司债券及相关授权事项。公司拟公开发行不超过30亿元公司债券，用于偿还有息负债、支持投资并购、补充流动资金等。目前CDE平台登记非诺贝特酸胆碱原料药生产企业共9家，阿齐沙坦原料药共13家。本次检查结果不会对公司业绩产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700000389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0175","BK0028","BK0239","BK0185","600062","BK0010"],"gpt_icon":0},{"id":"2564085958","title":"华润双鹤(600062.SH)控股子公司浙江新赛科通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2564085958","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564085958?lang=zh_cn&edition=full","pubTime":"2025-09-02 17:37","pubTimestamp":1756805868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司控股子公司浙江新赛科药业有限公司(简称“浙江新赛科”)收到浙江省药品监督管理局颁发的非诺贝特酸胆碱原料药、阿齐沙坦原料药《药品GMP符合性检查告知书》。公司本次通过药品GMP符合性检查，表明公司产品生产质量管理符合GMP要求，将有利于公司继续保持稳定的产品质量和持续稳定的生产能力，以满足相关药品的市场需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1340567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","600062","BK0185","BK0188","BK0239","BK0028","BK0010"],"gpt_icon":0},{"id":"2563832096","title":"华润双鹤：氯化钾注射液获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2563832096","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563832096?lang=zh_cn&edition=full","pubTime":"2025-08-31 15:38","pubTimestamp":1756625912,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","BK0188","MCNHmain","CNHmain","BK0185","BK0175","MUCmain","UCmain","600062","CYB","BK0010","159891","BK0028"],"gpt_icon":0},{"id":"2563832093","title":"华润双鹤(600062.SH)：氯化钾注射液获得药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2563832093","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563832093?lang=zh_cn&edition=full","pubTime":"2025-08-31 15:37","pubTimestamp":1756625871,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司安徽双鹤药业有限责任公司(简称“安徽双鹤”)收到了国家药品监督管理局(简称“国家药监局”)颁发的氯化钾注射液《药品补充申请批准通知书》。经审查，批准本品增加10ml:1.5g规格的补充申请，核发药品批准文号。本品通过仿制药质量和疗效一致性评价。氯化钾注射液用于治疗和预防低钾血症，适用于无法口服补钾时。氯化钾注射液获得《药品补充申请批准通知书》将有利于未来的市场销售和市场竞争，并为后续开展仿制药一致性评价积累了宝贵的经验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1339471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)：氯化钾注射液获得药品补充申请批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0188","BK0185","600062","BK0175","BK0239","BK0010"],"gpt_icon":0},{"id":"2562716184","title":"华润双鹤：公司药品获批准通知书及药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2562716184","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562716184?lang=zh_cn&edition=full","pubTime":"2025-08-27 16:53","pubTimestamp":1756284816,"startTime":"0","endTime":"0","summary":"华润双鹤公告，近日公司收到国家药品监督管理局颁发的盐酸甲氧氯普胺注射液《药品补充申请批准通知书》和利丙双卡因乳膏《药品注册证书》。盐酸甲氧氯普胺注射液用于镇吐，包括化疗、放疗、手术引起的呕吐等症状。利丙双卡因乳膏用于皮肤局部麻醉，如针穿刺、外科手术等。公司针对盐酸甲氧氯普胺注射液累计研发投入为225.56万元，利丙双卡因乳膏为993.67万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/27165352740514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0185","BK0010","BK0188","BK0028","600062","BK0239","BK0175"],"gpt_icon":0},{"id":"2562293448","title":"股市必读：华润双鹤中报 - 第二季度单季净利润同比下降12.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562293448","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562293448?lang=zh_cn&edition=full","pubTime":"2025-08-25 08:44","pubTimestamp":1756082653,"startTime":"0","endTime":"0","summary":"股本股东变化截至2025年6月30日，华润双鹤股东户数为5.74万户，较3月31日减少1645户，减幅为2.78%。业绩披露要点华润双鹤2025年中报显示，公司主营收入57.42亿元，同比下降3.16%；归母净利润9.75亿元，同比下降6.79%；扣非净利润9.33亿元，同比上升1.21%。其中2025年第二季度，公司单季度主营收入26.63亿元，同比下降4.36%；单季度归母净利润4.69亿元，同比下降12.11%；单季度扣非净利润4.47亿元，同比下降14.7%；负债率29.65%，投资收益4655.4万元，财务费用56.71万元，毛利率59.8%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082500002017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062"],"gpt_icon":0},{"id":"2561258434","title":"每周股票复盘：华润双鹤（600062）股东户数减少，半年度营收下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2561258434","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561258434?lang=zh_cn&edition=full","pubTime":"2025-08-24 05:02","pubTimestamp":1755982937,"startTime":"0","endTime":"0","summary":"截至2025年8月22日收盘，华润双鹤报收于20.34元，较上周的20.43元下跌0.44%。本周，华润双鹤8月19日盘中最高价报20.7元。业绩披露要点：2025年上半年华润双鹤主营收入57.42亿元，同比下降3.16%。公司公告汇总：华润双鹤拟向全体股东每10股派发现金红利1.00元（含税）。股本股东变化近日华润双鹤披露，截至2025年6月30日公司股东户数为5.74万户，较3月31日减少1645.0户，减幅为2.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082400000917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062"],"gpt_icon":0},{"id":"2561450282","title":"华润双鹤与河南投资集团签署战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2561450282","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561450282?lang=zh_cn&edition=full","pubTime":"2025-08-23 10:49","pubTimestamp":1755917347,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0010","600062","BK0175","BK0185","BK0239","BK0188","BK0028"],"gpt_icon":0},{"id":"1179329794","title":"华润医药-华润双鹤拟每10股派发现金股息人民币1元（含税）","url":"https://stock-news.laohu8.com/highlight/detail?id=1179329794","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179329794?lang=zh_cn&edition=full","pubTime":"2025-08-22 17:25","pubTimestamp":1755854719,"startTime":"0","endTime":"0","summary":"华润医药-华润双鹤拟每10股派发现金股息人民币1元（含税）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1570","600062","03320","BK0188","BK0185","BK0175","BK0028","BK0010","BK1191"],"gpt_icon":0},{"id":"2561942472","title":"华润双鹤：2025年上半年净利润同比减少6.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561942472","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561942472?lang=zh_cn&edition=full","pubTime":"2025-08-22 16:40","pubTimestamp":1755852054,"startTime":"0","endTime":"0","summary":"华润双鹤公告，2025年上半年营业收入57.42亿元，同比下降3.16%。净利润9.75亿元，同比减少6.79%。公司2025年半年度拟以实施权益分派股权登记日登记的总股本为基数分配利润，拟向全体股东每10股派发现金红利1元(含税)。根据截至2025年6月30日公司总股本10.39亿股，扣除2025年7月30日回购注销79013股限制性股票后的股份数量10.39亿股，以此计算合计拟派发的现金红利为1.04亿元(含税)。本次派发现金红利占2025年半年度归属于上市公司股东的净利润的10.65%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/22164052619049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["600062"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1762419007178,"stockEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":0.0354},{"period":"3month","weight":-0.0407},{"period":"6month","weight":0.0482},{"period":"1year","weight":-0.0877},{"period":"ytd","weight":-0.0037}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":0.0223},{"period":"3month","weight":0.0906},{"period":"6month","weight":0.1877},{"period":"1year","weight":0.1719},{"period":"ytd","weight":0.1842}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润双鹤药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"57726人(较上一季度增加0.51%)","perCapita":"17888股","listingDate":"1997-05-22","address":"北京市朝阳区望京利泽东二路1号","registeredCapital":"103875万元","survey":" 华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务和输液业务三大业务。公司的主要产品是输液业务平台、慢病业务平台、专科业务平台、原料药、复方利血平氨苯蝶啶片(0号)、左炔诺孕酮片(金毓婷)、胞磷胆碱钠片(诺百益)、缬沙坦氢氯噻嗪片(复穗悦)、软袋(含直立式)。","listedPrice":6.69},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润双鹤,600062,华润双鹤股票,华润双鹤股票老虎,华润双鹤股票老虎国际,华润双鹤行情,华润双鹤股票行情,华润双鹤股价,华润双鹤股市,华润双鹤股票价格,华润双鹤股票交易,华润双鹤股票购买,华润双鹤股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}